Introduction
Esophageal varices and Mallory Weiss syndrome are the two major esophageal bleeding disorders. Despite significant advances in endoscopic and medical treatment in recent years, management of these esophageal bleeding disorders remains a challenging problem. This review focuses on studies published in the previous 12 months that provided further understanding of the appropriate treatment of various esophageal bleeding disorders.
Esophageal varices
Management of esophageal varices remains one of the most challenging problems in therapeutic endoscopy. With advances in endoscopic therapy, recent data indicate a substantial reduction in the mortality rate from variceal hemorrhage from 30 to 50% to less than 30%. In a study involving 725 patients with variceal bleeding, the overall short-term mortality after index bleeding was only 12.9% [1] . In another retrospective analysis involving 231 patients, the in-hospital, 6-week, and overall mortality rates were reported to be only 14.2%, 17.5%, and 33.5% respectively [2] . The improved mortality is probably attributed to common use of emergency endoscopy, advances in endoscopic therapy and vasoactive agents, and the increased application of portosystemic shunts. However, the early rebleeding rate of esophageal varices is still as much as 30% despite effective initial control of acute hemorrhage and significant reduction in mortality.
Endoscopic therapy of acute variceal hemorrhage
Sclerotherapy used to be the first-line endoscopic therapy for esophageal variceal hemorrhage. It has largely been superseded by band ligation because of a significantly higher incidence of complications and a lower success rate of hemostasis. The relative effectiveness of sclerotherapy and pharmacologic treatment has also been addressed in a meta-analysis of 15 randomized controlled trials comparing sclerotherapy with various pharmacologic treatments including vasopressin and somatostatin analogs [3] . The meta-analysis concluded that sclerotherapy was not superior to any vasoactive agent for rebleeding, blood transfusions, and mortality. Furthermore, it was associated with significantly more adverse events. The available evidence further deprecates the use of sclerotherapy as a first-line treatment of esophageal varices.
Band ligation has been widely accepted as the first-line endoscopic treatment of esophageal varices. However, there has been concern regarding the risk of fundal varix formation and worsening of portal hypertensive gastropathy after band ligation. This potential deleterious impact on the portal pressure gradient was evaluated in a prospective study [4] . Twenty-two cirrhotic patients with variceal hemorrhage underwent measurement of hepatic venous pressure gradient before and after band ligation. It was found that band ligation did not alter the hepatic venous pressure gradient. Among patients with worsening of portal hypertensive gastropathy or development of fundal varices, the pressure gradient remained unaltered. This finding suggests that worsening of portal hypertensive gastropathy and development of fundal varices are likely the result of progression of cirrhosis instead of band ligation.
Endoscopic clipping is an emerging endoscopic treatment modality for variceal hemorrhage. A recent, prospective, randomized study involving 40 patients with esophageal variceal hemorrhage compared the efficacy of endoscopic clipping and variceal ligation [5] . It was found that initial hemostasis was achieved in all patients who underwent clipping, but two patients in the band ligation group experienced hemostatic failure. Endoscopic clipping achieved a significantly higher variceal eradication rate (89% vs 76%) and fewer treatment sessions (3 vs 4) than band ligation. Further studies are required to evaluate the rebleeding rate after initial successful hemostasis and its safety profile.
Pharmacologic therapy of acute variceal hemorrhage
Pharmacologic therapy remains an important component in the management of acute variceal hemorrhage. There have been controversies regarding the best pharmacologic therapy in acute variceal hemorrhage. Because of their superior cardiovascular safety compared with vasopressin, somatostatin and its analogs are preferred pharmacologic agents. On the other hand, terlipressin is a new vasopressin analog with good cardiovascular safety, and it has the additional advantage of easy administration by intravenous injection. The efficacy and safety of terlipressin was evaluated in a systemic review of 20 randomized trials involving 1609 patients that compared terlipressin with placebo, balloon tamponade, endoscopic treatment, octreotide, somatostatin, or vasopressin [6] . Terlipressin reduced mortality (RR, 0.66), failure of hemostasis (RR, 0.63), and the number of emergency procedures required for uncontrolled bleeding or rebleeding (RR, 0.72). When used as adjuvant therapy to endoscopic sclerotherapy, terlipressin was also the only pharmacologic agent that appeared to reduce mortality (RR, 0.74; 95% CI, 0.53 to 1.04). However, hemostasis was achieved more frequently with octreotide compared with terlipressin (RR, 1.62), based on unblinded studies. Adverse events were similar between terlipressin and the other comparison groups except for vasopressin, which caused more withdrawals as a result of adverse events. This study further supports the safety and effectiveness of terlipressin for acute esophageal variceal hemorrhage.
Secondary prophylaxis
No consensus has yet been reached on the most effective strategy for secondary prophylaxis of esophageal variceal hemorrhage. Nonselective ␤-blockers, with or without isosorbide mononitrate, have been used extensively as the first-line medical therapy for secondary prophylaxis. Other commonly used treatment modalities include band ligation and a combination of band ligation with medical therapy. With the advent of N-butyl-2cyanoacrylate (histoacryl) in the treatment of bleeding gastric varices, the role of repeated histoacryl injection in secondary prophylaxis of variceal hemorrhage was evaluated in a small, randomized study involving 41 patients with first variceal hemorrhage, mostly from esophageal varices [7] . During a 6-year follow-up period, there was no difference in the incidence of rebleeding and mortality compared with propranolol. However, the substantially higher incidence of complications (50% vs 10%) precluded the application of histoacryl in secondary prophylaxis. A transjugular intrahepatic portosystemic shunt has been shown consistently to be superior in the prevention of variceal hemorrhage, but it should not be used as a first-line treatment because of the lack of survival benefit and the significant risk of aggravating hepatic encephalopathy [8•]. A transjugular intrahepatic portosystemic shunt should be reserved as rescue therapy for failure of medical and endoscopic therapies. Photodynamic therapy has recently been tested in an animal model as a novel treatment of esophageal varices [9] . Photodynamic therapy destroys the endothelium, results in thrombus formation, and eventually obliterates the vein. The safety and efficacy of photodynamic therapy needs further study.
Predictors of variceal hemorrhage
Because variceal hemorrhage accounts for a significant proportion of morbidity and mortality in cirrhotic patients, the current practice is to screen all cirrhotic patients at the time of diagnosis by upper endoscopy for varices. Patients with large varices should be treated with nonselective ␤-blockers to reduce the incidence of first variceal hemorrhage. However, fewer than 50% of cirrhotic patients have varices at screening endoscopy, and 75% of patients have small varices, which have low risk of bleeding. Hence, screening endoscopy can be avoided in many patients if noninvasive surrogate markers can be used to identify a high-risk group. Giannini et al. [10••] studied various clinical, biochemical, and ultrasonographic parameters that predicted the presence of esophageal varices. A total of 145 cirrhotic patients were evaluated retrospectively for predictors of esophageal varices, and a subsequent group of 121 patients were then assessed prospectively to test the reproducibility of these markers. All patients underwent a complete biochemical workup, upper digestive endoscopy, and ultrasonographic measurement of spleen bipolar diameter. During the retrospective analysis, the platelet count-to-spleen diameter ratio was the only independent parameter associated with the presence of esophageal varices on multivariate analysis. A ratio cutoff value of 909 had a 100% negative predictive value for a diagnosis of esophageal varices, with high reproducibility. The use of the platelet countto-spleen diameter ratio strategy was also far more costeffective compared with routine endoscopic screening for all patients. Another study involving 184 cirrhotic patients studied 17 potential factors and found that platelet count, spleen size, and presence of ascites by ultrasound were independent predictors of large esophageal varices [11] . Using mean values as cutoff points, 83% of patients with a platelet count less than 118 × 10 9 /L, a spleen length of more than 135 mm, and with ascites had esophageal varices. Endoscopy could probably be avoided safely in cirrhotic patients with none of these predictive factors, because large varices are absent in this group of patients.
The incidence and natural history of small esophageal varices detected by screening endoscopy has been poorly understood. A prospective study followed 206 cirrhotic patients, 113 without varices and 93 with small esophageal varices, with yearly endoscopic surveillance as long as 5 years [12] . The rate of incidence of esophageal varices was 5% at 1 year and 28% at 3 years, with a rate of esophageal varices progression of 12% (range, 5.6 to 18.4%) at 1 year and 31% (range, 21.2 to 40.8%) at 3 years. Postalcoholic origin of cirrhosis, evidence of decompensation (Child-Pugh class B or C), and the finding of red wale marks at first examination were predictors for the progression of esophageal varices. However, the presence of red wale signs at first endoscopy was the only independent predictor of variceal bleeding.
Endoscopic ultrasound has also been evaluated to predict the risk of bleeding from esophageal varices. Twenty-eight patients with portal hypertension and esophageal varices, but no prior history of variceal bleeding, were evaluated using endoscopic ultrasound [13•]. The sum of the cross-sectional surface area (CSA) of all the esophageal varices in the distal esophagus was determined. It was found that patients with subsequent occurrence of variceal hemorrhage had a significantly larger CSA. There was a 76-fold increase per year in the risk of future variceal bleeding for each 1 cm 2 increase in variceal CSA. Using a cutoff value for the CSA of 0.45 cm 2 , the sensitivity and specificity for future variceal bleeding above and below this point is 83% and 75% respectively. Recently, gadolinium-enhanced MRI has also been reported to be highly sensitive and accurate for the detection of large esophageal varices [14] . The combination of assessment of liver function, and endoscopic and radiologic findings allows more accurate prediction of the risk of progression and bleeding of esophageal varices.
Primary prophylaxis
Medical therapy with nonselective ␤-blockers (propranolol, nadolol) remains the most widely accepted and the most cost-effective strategy for primary prophylaxis of variceal hemorrhage [15, 16] . However, 30% of patients develop intolerance to propranolol and require discontinuation of therapy. Furthermore, a significant proportion of patients are "nonresponders." Although a combination of propranolol and isosorbide mononitrate achieved a greater reduction in portal pressure than propranolol alone, combination medical therapy has not been shown to give additional benefits in preventing first variceal hemorrhage or in improving survival [17••] . Other novel pharmacologic agents, such as a weekly depot injection of long-acting somatostatin analogs, have been suggested as an alternative to propranolol, but studies of its hemodynamic effects on portal hypertension have been disappointing [15] . To date, the role of endoscopic band ligation in secondary prophylaxis is indisputable and it begins to have a competitive edge over medical therapy in primary prevention. It has been found to be safe and highly effective even in children [18] . Yet, whether band ligation is more effective than medical therapy for primary prevention is still a subject of dispute, because previous studies were flawed. Recently, the efficacy and safety of band ligation compared with ␤-blockers for primary prevention of variceal bleeding was addressed again in another randomized trial involving 100 patients with high-risk esophageal varices [19••] . In the ligation group, variceal obliteration was achieved in 82%. In the nadolol group, a mean daily dose of 60 mg nadolol was administered. Esophageal variceal bleeding occurred in 10% of patients in the ligation group and in 18% of patients in the nadolol group during the 22month follow-up. There was no statistically significant difference in the incidence of bleeding, complications, and survival. In contrast to previous trials, this study failed to show any advantage of band ligation despite a comparable safety profile with medical therapy. With the high failure rates of ␤-blocker therapy, the best treat-ment modality for primary prophylaxis of esophageal varices remains an area of major research interest.
Mallory Weiss syndrome
Mallory Weiss syndrome, which refers to laceration of the gastroesophageal junction, accounts for 5 to 15% of cases of upper gastrointestinal bleeding. The bleeding stops spontaneously in 90% of patients, and these patients can be managed conservatively. Endoscopic therapy is required when there are risk factors such as bleeding diathesis, evidence of active bleeding (such as hematemesis and hemodynamic instability), or presence of stigmata of recurrent bleeding (such as visible vessel and adherent clot). Endoscopic injection of adrenaline or saline has been the treatment of choice for Mallory Weiss tear. Other modalities include electrocoagulation and ligation. In recent years, endoscopic clipping is emerging as an attractive alternative modality of treatment. Endoscopic clipping has been shown to have comparable success rate of initial hemostasis [20] and an even lower rebleeding rate compared with adrenaline injection. Endoscopic clipping may be the preferred treatment for deeper extension of Mallory Weiss tear with an esophageal perforation.
Arterio-esophageal fistula and other vascular diseases
Aortoesophageal fistula is a rare and lethal disorder that may result from primary diseases of the aorta or esophagus, aortic bypass graft, ingestion of foreign body, trauma, surgical procedure, or instrumentation. Tuberculous fistula resulting from tuberculous mediastinitis can cause aortoesophageal fistula, which may mimic Dieulafoy lesion [21] . An anomalous aortic arch system or spinal deformities predispose to direct contact between the aorta and the esophagus. Dense, fibrous adhesions between the aorta and the esophagus resulting from multiple previous spinal correction procedures also contribute to the formation of arterio-esophageal fistula. Bleeding can be provoked by a simple procedure, such as nasogastric tube placement. It is of utmost importance to recognize early "sentinel" hematemesis before massive hemorrhage, because this may allow for timely surgical intervention to prevent fatal exsanguination [22] . In situ allograft replacement usually in association with subtotal esophagectomy appears to be an excellent salvage modality whenever emergency surgery is feasible [23] . Mediastinal bronchial artery aneurysm is a rare condition that often presents with respiratory symptoms resulting from rupture into the pleural parenchyma. However, when it develops mediodorsally and compresses the esophagus, it may cause dysphagia and even hematemesis. MRI and probe thoracoscopy are preferred to CT and endoscopic ultrasound because this condition can often be misdiagnosed as submucosal tumor of the esophagus [24] .
Opportunistic infection affecting the esophagus
Opportunistic infection is an emerging entity of esophageal bleeding disorders. Cytomegalovirus esophageal ulcer can result in serious life-threatening bleeding complications. Visceral bacillary angiomatosis can occur in the absence of cutaneous lesions. It can present as ulcerated nodular lesions in the esophagus, which can be misdiagnosed as Kaposi sarcoma. A biopsy of bacillary angiomatosis showed mucosal ulceration with a proliferation of vascular channels associated with neutrophils and clumps of purplish, granular bacterial colonies, which were highlighted by Warthin-Starry stain [25] .
Other esophageal bleeding disorders
Other causes of bleeding in the esophagus include esophageal cancer, erosive esophagitis, corrosive injury, and acute esophageal necrosis (black esophagus). Bleeding from inoperable esophageal cancer can be difficult to treat, but several treatment modalities are available for the palliative control of bleeding. External beam radiation therapy, surgical resection, and endoscopic interventions including photodynamic therapy [26] , Nd:YAG laser, and brachytherapy have been reported with variable success. Bleeding from erosive esophagitis is mostly selflimiting and amenable to medical therapy, such as a potent acid suppressant and a mucoprotective agent. Black esophagus is a rare condition that is defined as a dark pigmentation of the esophagus associated with histologic mucosal necrosis. Distal esophagus is primarily involved, but it can extend proximally. The disease always ends sharply at the gastroesophageal border, and the gastric mucosa is spared. Most cases have no known etiology, although ischemia, nasogastric tube trauma, infection, gastric outlet obstruction, gastric volvulus, and hypersensitivity to antibiotics have all been suggested as possible causes. The best treatment for this condition is still unclear.
Conclusion
With the advent of endoscopic band ligation and the extensive use of vasoactive agents, mortality from variceal hemorrhage has been substantially reduced. Although nonselective ␤-blockers are still the most widely accepted treatment for both primary and secondary prophylaxis, their usefulness is limited by intolerance and a high incidence of nonresponse. Endoscopic band ligation is therefore increasingly used as an alternative strategy for primary prophylaxis. A transjugular intrahepatic portosystemic shunt should be reserved as rescue therapy for failure of medical and endoscopic treatments. A combination of various clinical, laboratory, and endosonographic parameters accurately predicts the risk for variceal hemorrhage. The streamlined screening strategy allows more cost-effective use of endoscopy and prompt prophylactic treatment for high-risk esophageal varices. For Mallory Weiss syndrome, endoscopic clipping is an emerging treatment modality, especially for deep laceration with risk of perforation.
